Gastrointestinal symptoms on the rise, but still fewer than before the COVID-19 pandemic In 2022, the number of enteric infections – which mainly cause gastrointestinal symptoms – was higher than it was in the previous two years. However, the total number of infections was still lower than before the coronavirus pandemic.
Broad approach needed against pharmaceutical residues in environment We can all help to reduce pollution of the environment by pharmaceutical residues.
Icy air measurements Bernice Notenboom’s Arctic March expedition team has reached the summit of Greenland. She has conquered the 3500-metre high summit on Greenland with functioning air measuring equipment.
Vaccination using needles: there are alternatives Dr Hoang Hirschberg, employed at RIVM, has carried out PhD research into three alternatives for needle injections. She concluded that all alternatives have advantages and limitations.
Injection needles: fact-finding and risk assessment of excess adhesive Commissioned by the Dutch Health Care Inspectorate (IGZ), RIVM investigated whether excess adhesive is present in two types of injection needles from the Terumo Company (K-Pack II and Neolus).
Points of special interest in home treatment with complex medical technologies Patients are increasingly being treated with complex medical technologies in their own home. This offers great benefits, however, it also introduces risks.
Climate reporter Bernice Notenboom arrives in Greenland for continuation of climate expedition Climate reporter and expedition leader Bernice Notenboom and her team left for Greenland on 4 May 2015 for the second part of the Arctic March.
Mental care still the most expensive of all In 2011, 19.6 billion euros was spent on the treatment of mental disorders. This amounted to 22% of the total expenditure on health and welfare during that year.
Risks of eHealth technology RIVM and Nictiz have made an overview of the risks that eHealth applications may entail and how these risks can be controlled.
Key organisations unite to improve benefit and risk assessments of vaccines Leading organisations have joined forces to launch a unique project that will pave the way for a pan-European framework for rapidly assessing and communicating the benefits and risks of vaccines.